RGEN Stock Analysis: Buy, Sell, or Hold?
RGEN - Repligen Corp
$112.39
2.27 (2.06%)
▲
5d:
-3.4%
30d:
-12.69%
90d:
-32.38%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 05, 2026
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: RGEN appears deeply undervalued. Market expects -13.5% annual earnings decline despite 160% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: RGEN appears deeply undervalued. Market expects -13.5% annual earnings decline despite 160% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$122.09
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$75.81
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $112.39, which is considered oversold relative to its 30-day fair value range of $116.12 to $132.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 43.9) compared to its historical average (67.8). Remarkably, the market is currently pricing in an annual earnings decline of 13.5% over the next few years. This pessimistic expectation contrasts with the company's recent 160.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, RGEN is in a strong downtrend. The price is currently testing key support at $109.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $186.82 (+69.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RGEN is in a strong downtrend. The price is currently testing key support at $109.66. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $186.82 (+69.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$116.12 -
$132.56
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 69.7% below Wall St target ($186.82)
Fair Price Analysis
30-Day Fair Range
$116.12 -
$132.56
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$109.66
Resistance Level
$122.62
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.91
Wall Street Target
$186.82
(+69.7%)
Revenue Growth (YoY)
18.1%
Earnings Growth (YoY)
160.0%
Profit Margin
6.6%
Valuation Discount vs History
-13.5% cheaper
PE vs Historical
43.9 vs 67.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.5%
(market-implied from PE analysis)
1-Year Target
$99.11
(-10%)
2-Year Target
$89.20
(-19%)
3-Year Target
$80.28
(-27%)
3-Yr Target (if PE normalizes)
(PE: 44→68)
$123.95
(+13%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 43.9, Growth: 27.7%)
$229.43
(+108%)
Base:
(SPY PE: 22.4, Growth: 27.7%)
$117.04
(+6%)
Bear:
(PE: 19.0, Growth: 27.7%)
$99.48
(-10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (57x PE), but valuation improves significantly next year (44x PE) as earnings recover.
Forward PE: 57.47 | Forward EPS (Implied): $2.02
Bull Case
$140.49
(+21%)
Analyst growth 15.0%, PE expands to 60.3
Base Case
$116.35
(0%)
Market implied 0.0%, PE stable at 57.5
Bear Case
$89.01
(-24%)
Severe decline -15.0%, PE contracts to 51.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 43.9 to 67.8
Stabilization Target:
$170.03
(+54.4%)
PE Expansion Potential:
+54.4%
Share & Embed Analysis
Last updated: March 30, 2026 11:58 AM ET
Data refreshes hourly during market hours. Next update: 12:58 PM
Data refreshes hourly during market hours. Next update: 12:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
1
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Karen A Dawes
SELL
275 shares
2025-12-17
James Bylund
SELL
2191 shares
2025-11-18
James Bylund
SELL
2191 shares
2025-11-18
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$607 | 51 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$94 | 55 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$318 | 63 BUY |
|
RMD
ResMed Inc |
BUY
19 analysts |
$297 | 61 BUY |
|
AVTR
Avantor Inc |
HOLD
21 analysts |
$11 | 58 HOLD |
